2-methyl-thieno-benzodiazepine

• US 5,605,897 A
• Filed: 02/13/1995
• Issued: 02/25/1997
• Est. Priority Date: 04/23/1991
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company, Lilly Industries Limited (Eli Lilly and Company)
• Original Assignee: Eli Lilly and Company, Lilly Industries Limited (Eli Lilly and Company)
• Inventors: Chakrabarti, Jiban K., Hotten, Terrence M., Tupper, David E., Beasley, Charles M. Jr.
• Primary Examiner(s): Datlow, Philip I.
• Application Number:
  US08/387,498
• Time in Patent Office: 743 Days
• Field of Search: 514/220
• US Class Current: 514/220
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine

Abstract

Olanzapine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##

Claims

1. A method of treating a patient suffering from or susceptible to a pathological psychological condition selected from the group consisting of Moderate Mental Retardation;

Severe Mental Retardation;

Profound Mental Retardation;

Autistic disorder;

Pervasive Development Disorder NOS;

Conduct Disorder, Group Type;

Conduct Disorder, Solitary Aggressive Type;

Tourette'"'"'s Disorder;

Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delirium;

Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions;

Bipolar Disorder NOS;

Personality Disorders, Paranoid;

Personality Disorders, Antisocial; and

Personality Disorders, Borderline;

which comprises administering to a patient in need thereof an effective amount of olanzapine, or an acid addition salt thereof.

2. A method of claim 1 wherein the condition is selected from the group consisting of Bipolar Disorder NOS;

Personality Disorders, Paranoid;

Personality Disorders, Antisocial; and

Personality Disorders, Borderline.

3. A method of claim 1 wherein the condition is selected from the group consisting of Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delirium;

and Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions.

4. A method of claim 1 wherein the effective amount is from 1 to 20 mg per day of olanzapine, or an acid addition salt thereof.